Data / Drug companies / Curia New York, Inc.
Curia New York, Inc.: 40 products in the FDA NDC directory, labeler code 65392
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Curia New York, Inc. (labeler code 65392) lists 40 products in the FDA National Drug Code Directory. By type: 40 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on September 28, 2026.
The request: Watch Curia New York, Inc. (FDA labeler code 65392): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 65392
- Products in commercial distribution
- 40
- Packages
- 40
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule II 8
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 10, 1942
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 28 | 70% |
| Bulk ingredients for compounding | 12 | 30% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 40 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 40 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Duvelisib | 65392-3426 | Powder | Bulk ingredients | September 28, 2026 |
| Sodium thiosulfate pentahydrate | 65392-3403 | Powder | Bulk ingredients | December 12, 2024 |
| Sndx-5613 | 65392-3415 | Powder | Bulk ingredients | November 10, 2023 |
| Sndx-5613 | 65392-3402 | Powder | Bulk ingredients | November 10, 2023 |
| Mgl-3196 | 65392-3203 | Powder | Bulk ingredients | November 9, 2023 |
| Palovarotene | 65392-3414 | Powder | Bulk ingredients | October 13, 2023 |
| Cantharidin | 65392-3416 | Powder | Bulk ingredients | July 21, 2023 |
| Epinephrine | 65392-1405 | Powder | Bulk ingredients | January 8, 2019 |
| Cetalkonium chloride | 65392-1201 | Powder | Bulk ingredients | May 2, 2018 |
| Amphetamine aspratate monohydrate | 65392-0117 | Powder | Bulk ingredients | May 2, 2018 |
| Brigatinib | 65392-3311 | Powder | Bulk ingredients | May 1, 2018 |
| Mangafodipir trisodium | 65392-2204 | Powder | Bulk ingredients | May 1, 2018 |
| Ambenonium chloride | 65392-1002 | Powder | Bulk ingredients | May 1, 2018 |
| Dextroamphetamine saccharate | 65392-0115 | Powder | Bulk ingredients | May 1, 2018 |
| Amphetamine sulfate | 65392-0110 | Powder | Bulk ingredients for compounding | April 24, 2018 |
| Lifitegrast | 65392-2803 | Powder | Bulk ingredients for compounding | July 11, 2016 |
| Belinostat | 65392-2509 | Powder | Bulk ingredients for compounding | July 3, 2014 |
| Tedizolid phosphate | 65392-2912 | Powder | Bulk ingredients | June 20, 2014 |
| Alogliptin | 65392-2813 | Powder | Bulk ingredients for compounding | January 25, 2013 |
| Enzalutamide | 65392-2209 | Powder | Bulk ingredients for compounding | August 31, 2012 |
| Dexmethylphenidate hydrochloride | 65392-3418 | Powder | Bulk ingredients | June 26, 2012 |
| Pralatrexate | 65392-2510 | Powder | Bulk ingredients | September 24, 2009 |
| Racepinephrine hydrochloride | 65392-2701 | Powder | Bulk ingredients | June 6, 2008 |
| Lisdexamfetamine dimesylate | 65392-0118 | Powder | Bulk ingredients for compounding | February 23, 2007 |
| Vorinostat fine | 65392-3102 | Powder | Bulk ingredients for compounding | October 6, 2006 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.